CRMD - NASDAQ
CorMedix Inc.
$8.23
+0.73%CorMedix Inc., a biopharmaceutical company, focuses on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases in the United States and internationally. Its lead product candidate is DefenCath/Neutrolin, a novel anti-infective solution for the reduction and prevention of catheter-related infections and thrombosis in patients requiring central venous catheters in clinical settings, such as hemodialysis, total parenteral nutrition, and oncology. The company was formerly known as Picton Holding Company, Inc. and changed its name to CorMedix, Inc. in January 2007. CorMedix Inc. was incorporated in 2006 and is based in Berkeley Heights, New Jersey.
At a Glance
Live SnapshotCorMedix Inc. Profit Bridge
Profitability Analysis
Gross Margin
Exceptional pricing power and cost management. The company retains over half of revenue after direct costs.
Operating Margin
Outstanding operational efficiency. The company generates substantial profit from core operations.
Net Profit Margin
Exceptional profitability. The company converts a significant portion of revenue to bottom-line earnings.
Effective Tax Rate
Below-average tax rate suggests effective tax planning, favorable jurisdictions, or tax credits.
Profitability Insight
Exceptional profitability across all levels: Strong pricing power, efficient operations, and healthy bottom line indicate a high-quality business with sustainable competitive advantages.
CorMedix Inc. Income Statement
CRMD • NASDAQ
| CorMedix Inc. Income Statement | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 | Dec 2015 | Dec 2014 | Dec 2013 | Dec 2012 | Dec 2011 | Dec 2010 | Dec 2009 | Dec 2008 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
REVENUE | ||||||||||||||||||
311.7M | 43.5M | 0.0 | 65.4K | 190.9K | 239.2K | 283.3K | 429.8K | 329.3K | 224.1K | 210.1K | 189.3K | 2K | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | |
GROSS PROFIT | ||||||||||||||||||
(36M) | (3.2M) | (205.6K) | (3.7K) | (148.9K) | (204.8K) | (373.2K) | (396.8K) | (115K) | (366.7K) | (318.7K) | (445.8K) | (201.6K) | (0.0) | (0.0) | (0.0) | (0.0) | (1M) | |
275.7M | 40.3M | -205.6K | 61.7K | 42K | 34.4K | -90K | 33K | 214.4K | -142.6K | -108.6K | -256.5K | -199.6K | 0.0 | 0.0 | 0.0 | 0.0 | -1M | |
OPERATING INCOME | ||||||||||||||||||
(125.6M) | (62.6M) | (48.8M) | (30.7M) | (29.5M) | (27.3M) | (20.9M) | (26.9M) | (33.1M) | (24.6M) | (16.5M) | (8.6M) | (4.7M) | (3M) | (7.2M) | (8.5M) | (6.1M) | (3.8M) | |
(30.2M) | (58.7M) | (35.6M) | (20M) | (16.3M) | (13.9M) | (9.9M) | (8.1M) | (8.7M) | (8.9M) | (10.3M) | (7.3M) | (3.5M) | (1.9M) | (3.1M) | (3M) | (1.2M) | (691.9K) | |
(19.3M) | (3.9M) | (13.2M) | (10.7M) | (13.1M) | (13.4M) | (11.1M) | (18.8M) | (24.5M) | (15.7M) | (6.3M) | (1.3M) | (1.2M) | (1.2M) | (4.1M) | (5.5M) | (4.9M) | (3.1M) | |
150.1M | -22.4M | -49M | -30.6M | -29.4M | -27.2M | -21M | -26.9M | -32.9M | -24.8M | -16.7M | -8.9M | -4.9M | -3M | -7.2M | -8.5M | -6.1M | -4.8M | |
PRE-TAX INCOME | ||||||||||||||||||
(2.8M) | (36.4K) | (0.0) | (26.5K) | (15.9K) | (33.2K) | (787.5K) | (1.9K) | (5.6K) | (1.3K) | (4K) | (2.1K) | (1.4M) | (382.9K) | (12K) | (3.1M) | (2.1M) | (4.2M) | |
1.1M | 2.5M | 2.7M | 299.5K | -1.5K | 82.8K | -464.8K | 34.7K | 105.1K | 125.5K | 56.4K | 627.0 | -1.4M | -381K | 0.0 | -3.1M | -2.1M | -4.2M | |
(76.1M) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | -4.5K | (0.0) | (0.0) | (0.0) | (0.0) | (0.0) | |
-125K | 3M | 2.6M | 336.6K | -22.8K | 23.7K | -486K | 34.6K | -85.8K | 117.3K | -1.5M | -11.6M | -4.2M | -381K | 41.9K | -2.7M | -2.1M | -4.2M | |
150M | -19.3M | -46.3M | -30.3M | -29.5M | -27.2M | -21.5M | -26.8M | -33M | -24.6M | -18.2M | -20.5M | -9.1M | -3.4M | -7.2M | -11.2M | -8.1M | -9M | |
NET INCOME | ||||||||||||||||||
-13M | -1.4M | (0.0) | -585.6K | -1.3M | -5.2M | -5.1M | (36.4K) | -31.3K | (1.3K) | (4K) | (2.1K) | (0.0) | (2K) | -493.9K | -280.9K | (2.1K) | (0.0) | |
163.1M | -17.9M | -46.3M | -29.7M | -28.2M | -22M | -16.4M | -26.8M | -33M | -24.6M | -18.2M | -20.5M | -9.1M | -3.4M | -6.7M | -10.9M | -8.1M | -9M |
SEC Filings
CRMD - Filing history and reports
| Filing Type | Filing Date | Period Ending | Fiscal Year | Actions |
|---|---|---|---|---|
8-K 8-K 2026 N/A | May 14, 2026 | May 14, 2026 | 2026 | |
10-Q 10-Q 2026 Q1 Q1 | May 14, 2026 | March 31, 2026 | 2026 | |
DEF 14A DEF 14A 2026 N/A | April 29, 2026 | June 23, 2026 | 2026 | |
8-K 8-K 2026 N/A | April 27, 2026 | April 27, 2026 | 2026 | |
8-K 8-K 2026 N/A | March 06, 2026 | March 06, 2026 | 2026 | |
10-K 10-K 2025 FY FY | March 05, 2026 | December 31, 2025 | 2025 | |
8-K 8-K 2026 N/A | March 05, 2026 | March 05, 2026 | 2026 | |
8-K 8-K 2026 N/A | January 08, 2026 | January 05, 2026 | 2026 | |
8-K 8-K 2025 N/A | November 12, 2025 | November 12, 2025 | 2025 | |
10-Q 10-Q 2025 Q3 Q3 | November 12, 2025 | September 30, 2025 | 2025 |
Related Guides
Continue your CRMD research with focused valuation guides.
Research Paths
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.